1. Introduction {#sec1}
===============

1.1. Rationale {#sec1.1}
--------------

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), formerly known as the 2019 novel Coronavirus (2019-nCoV), is a newly emerging zoonotic agent that appeared in December 2019 and causes the Coronavirus Disease 2019 (COVID-19) \[[@bib1]\]. This pathogen results in a syndrome leading in some cases to a critical care respiratory condition, that requires specialized management at intensive care units (ICU) in many of them \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7]\]. The SARS-CoV-2, taxonomically, is currently part of the species of the SARS-related coronaviruses that belong to the subgenus *Sarbecovirus*. Together with the subgenuses *Embecovirus*, *Hibecovirus*, *Merbecovirus*, and *Nobecovirus*, that are part of the genus *Betacoronavirus* (order *Nidovirales*; suborder *Cornidovirineae*; family *Coronaviridae*; subfamily *Coronavirinae*) \[[@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]\].

Other Betacoronaviruses before have caused epidemics over the last two decades in Asia, as is the case of SARS-CoV in 2002--2003 in China \[[@bib10],[@bib15],[@bib16]\], and later with the Middle East Respiratory Syndrome (MERS-CoV) in 2012--2013 in Saudi Arabia \[[@bib17], [@bib18], [@bib19], [@bib20]\]. As expected, several similarities and differences in the epidemiology, clinical features, and management of SARS, MERS, and COVID have been identified \[[@bib3], [@bib4], [@bib5],[@bib20], [@bib21], [@bib22], [@bib23]\]. These are enveloped positive-strand RNA viruses isolated from bats that share sequence homology with isolates from humans, suggesting bats as natural hosts and reservoirs \[[@bib9],[@bib24], [@bib25], [@bib26], [@bib27]\]. Although the clinical picture of SARS, MERS, and COVID-19 seems to be similar, differences were noted \[[@bib4],[@bib5],[@bib21],[@bib28]\] since early reports. A full clinical characterization of this disease, as well as its laboratory and image characteristics, is required.

Although only two months have elapsed since the emergence of COVID-19, some studies and case reports have been already published in major international scientific and medical journals, from China and other countries with travel- and non-travel-related cases \[[@bib7],[@bib13],[@bib29],[@bib30]\]. Many of these reports have started to answer clinical questions, including evolution and outcomes, as well as potential risk factors, and clinical, laboratory and image findings; however, a systematic review to consolidate what has been learned from each study or reported case is to-date missing. Although systematic reviews and meta-analyses usually include randomized clinical trials (RCTs) and aim to provide a more precise estimate of the effect of a treatment or risk factor for disease, also have been extensively used, especially during the last decades, to synthesized observational studies \[[@bib31], [@bib32], [@bib33]\]. In many situations, RCTs are not feasible or available, and only data from observational studies are accessible \[[@bib33]\]. This is the case for the clinical, laboratory, and image features of COVID-19.

2. Objectives {#sec2}
=============

•To summarize the clinical, laboratory, and image features of COVID-19 reported in currently available observational studies.•To examine the outcome of COVID-19 cases, including risk factors, the proportion of patients requiring ICU and those with fatal outcomes.•To assess the prevalence of comorbidities among COVID-19 confirmed cases.

3. Methods {#sec3}
==========

3.1. Protocol and registration {#sec3.1}
------------------------------

This protocol follows the recommendations established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@bib34]\], and it has been reported in the International Prospective Register of Systematic Reviews (PROSPERO) database (ID 170643).

3.2. Eligibility criteria {#sec3.2}
-------------------------

We included published peer-reviewed articles that reported cases with demographical, clinical, laboratory, and image features of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) confirmed SARS-CoV-2 infection. For assessing clinical, laboratory and imaging characteristics eligible study designs were case-control, cohort studies, case reports, and case series. For assessing risk factors and outcomes only observational studies were included. Article language limit was not set, and we included publications from January 1, 2020 until February 23, 2020. Review articles, opinion articles and letters not presenting original data were excluded, as well as studies reporting cases with incomplete information.

3.3. Information sources and search strategy {#sec3.3}
--------------------------------------------

We conducted a systematic review using Medline/PubMed, Scopus, and Web of Science. The following search terms used: "Novel coronavirus," "Novel coronavirus 2019", "2019 nCoV", "COVID-19", "Wuhan coronavirus," "Wuhan pneumonia," and "SARS-CoV-2." The searches were concluded by February 23, 2020, and four different researchers independently evaluated search results.

3.4. Study selection {#sec3.4}
--------------------

The results of the initial search strategy were first screened by title and abstract. The full texts of relevant articles were examined for inclusion and exclusion criteria ([Fig. 1](#fig1){ref-type="fig"} ). When an article reported duplicate information from the same patient, the information of both reports was combined in order to obtain complete data, but only counted as a single case. Observational studies that reported the proportion of symptoms, laboratory characteristics and risk factors were included for quantitative synthesis (meta-analysis). Case reports were not included for the meta-analysis, as they do not have a denominator for any variables, but descriptive statistics were applied to them, to summarize their findings.Fig. 1Study selection and characteristics.Fig. 1

3.5. Data collection process and data items {#sec3.5}
-------------------------------------------

Data extraction forms including information on the type of publication, the publishing institution, country, year and date of publication, the number of reported cases, of cases at ICU, age, sex, comorbidities, clinical features (e.g., fever, cough), laboratory findings (e.g., white blood cell counts \[WBC\], biochemistry), imaging (e.g., chest X-ray), complications (e.g., acute respiratory distress syndrome, ARDS), outcome (e.g., death) were filled independently by four investigators. A fifth researcher checked the article list and data extractions to ensure there were no duplicate articles or duplicate information of the same patient and also resolved discrepancies about study inclusion.

3.6. Assessment of methodological quality and risk of bias {#sec3.6}
----------------------------------------------------------

For quality assessment, we used the Quality Appraisal of Case Series Studies Checklist of the IHE and specifically the critical appraisal tool to assess the quality of cross-sectional studies (AXIS) \[[@bib35],[@bib36]\]. Publication bias was assessed using a funnel-plot. A random-effects model was used to calculate the pooled prevalence and 95%CI, given variable degrees of data heterogeneity, and given the inherent heterogeneity in any systematic review of studies from the published literature. Egger\'s test for publication bias was also performed.

3.7. Statistical approach {#sec3.7}
-------------------------

Unit discordance for variables was resolved by converting all units to a standard measurement for that variable. Percentages and means ± standard deviation (SDs) were calculated to describe the distributions of categorical and continuous variables, respectively. Since individual patient information was not available for all patients, we report weighted means and SDs. The baseline data were analyzed using the Stata version 14.0, licensed for Universidad Tecnológica de Pereira.

The meta-analyses were performed using Stata, and the software OpenMeta\[Analyst\] \[[@bib37]\] and Comprehensive Meta Analysis ve.3.3® licensed for Universidad Tecnológica de Pereira, Colombia. Pooled prevalences and their 95% confidence intervals (95% CIs) were used to summarize the weighted effect size for each study grouping variable using the binary random-effects model (the weighting took into consideration the sample sizes of the individual studies), except for median age, where a continuous random-effect model was applied (DerSimonian-Laird procedure) \[[@bib38],[@bib39]\].

Measures of heterogeneity, including Cochran\'s Q statistic, the I^2^ index, and the tau-squared test, were estimated and reported. We performed subgroup analyses by age groups (adults or children). And meta-analyses for each of the variables of interest.

4. Results {#sec4}
==========

4.1. Study selection and characteristics {#sec4.1}
----------------------------------------

A total of 660 articles were retrieved using the search strategy, including 39 case reports. After screening by abstract and title, 64 articles were selected for full-text assessment. Of these, six were excluded due to lack of information on molecular diagnosis, and 58 were included for qualitative analysis, 19 of them for quantitative meta-analysis and 39 case reports for descriptive analysis ([Fig. 1](#fig1){ref-type="fig"}). The main characteristics of the included studies are shown in [Table 1](#tbl1){ref-type="table"} .Table 1Characteristics of the included studies on COVID-19, 2020. All patients confirmed by real-time RT-PCR.Table 1AuthorJournalDate (MM/DD)CountryStudy typeNQuality score[a](#tbl1fna){ref-type="table-fn"}ReferenceWMCHHHPNCICommission Report01/20ChinaCross-sectional13612\[[@bib64]\]Chaolin et al.Lancet01/24ChinaCross-sectional4119\[[@bib5]\]Li et al.NEJM01/29ChinaCross-sectional42519\[[@bib11]\]Chen et al.Lancet01/30ChinaCross-sectional9919\[[@bib4]\]Chung et al.Radiology02/04ChinaCross-sectional2112\[[@bib65]\]Chen et al.Chin J Tuberc Respir Dis02/06ChinaCross-sectional2912\[[@bib66]\]Wang et al.JAMA02/07ChinaCross-sectional13819\[[@bib67]\]Kui et al.Chin Med J02/07ChinaCross-sectional13712\[[@bib68]\]Chang et al.JAMA02/07ChinaCross-sectional1314\[[@bib69]\]To et al.Clin Infect Dis02/12ChinaCross-sectional1214\[[@bib70]\]COVID-19 team AustraliaTeam Report02/12AustraliaCross-sectional1512\[[@bib71]\]Yueying et al.Eur Radiol02/13ChinaCross-sectional6314\[[@bib72]\]Li et al.Preprint Lancet02/13ChinaCase series2414\[[@bib73]\]Feng et al.Radiology02/13ChinaCase series2112\[[@bib74]\]Liang et al.Lancet Oncology02/14ChinaCross-sectional159017\[[@bib41]\]Zhang et al.Chin J Tuberc Respir Dis02/15ChinaCase series912\[[@bib40]\]Feng et al.Chin J Pediatr02/17ChinaCase series1512\[[@bib75]\]Wang et al.Chin J Pediatr02/17ChinaCross-sectional3412\[[@bib76]\]Xiaobo et al.Lancet Respir Med02/21ChinaCross-sectional5217\[[@bib52]\][^2][^3]

Our review included 19 studies that were published between January 1, 2020, and February 21, 2020, most of them from China (18) and one from Australia ([Table 1](#tbl1){ref-type="table"}), including a total of 2874 patients, ranging from a case series of 9 \[[@bib40]\] to a cross-sectional study of 1590 \[[@bib41]\]. Although as of March 9, 2020, there have been more than 111,000 cases reported, these have not been included and published in studies available in the literature. Most studies were cross-sectional (15), and four were case series ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}, [Table 5](#tbl5){ref-type="table"} ). We analyzed 42 variables for the meta-analyses ([Table 6](#tbl6){ref-type="table"} ). Publication bias was assessed with a funnel plot for the standard error by logit event, with no evidence of bias ([Fig. S1](#appsec1){ref-type="sec"}). Additionally, the Egger test (P = 0.801) suggested that there was no notable evidence of publication bias.Table 2Demographical characteristics, ICU requirement, and comorbidities of the study subjects.Table 2AuthorDate (MM/DD)NMean Age (y-old)Age RangeSex (Male)N at ICUN (%)ReferenceComorbiditiesDiabetesHypertensionCardiovascular diseaseChronic obstructive pulmonary diseaseMalignanciesChronic liver diseaseWMCHHHPNCI01/20136-25-8966\-\-\-\-\-\-\--\[[@bib64]\]Chaolin et al.01/24414941-583013 (31.7)13 (31.7)8 (19.5)6 (14.6)6 (14.6)1 (2.4)1 (2.4)1 (2.4)\[[@bib5]\]Li et al.01/294255626-82240\-\-\-\-\-\-\--\[[@bib11]\]Chen et al.01/309955.521-826723 (23.2)50 (50.5)12 (12.1)-40 (40.4)1 (1.0)1 (1.0)-\[[@bib4]\]Chung et al.02/04215129-7713\-\-\-\-\-\-\--\[[@bib65]\]Chen et al.02/06295626-7921-16 (55.2)5 (17.2)8 (27.6)\--1 (3.4)2 (6.9)\[[@bib66]\]Wang et al.02/071385642-687536 (26.1)64 (46.4)14 (10.1)43 (31.2)20 (14.5)4 (2.9)10 (7.2)4 (2.9)\[[@bib67]\]Kui et al.02/071375720-8361-27 (19.7)14 (10.2)13 (9.5)10 (7.3)2 (1.5)2 (1.5)-\[[@bib68]\]Chang et al.02/07133434-4810\-\-\-\-\-\-\--\[[@bib69]\]To et al.02/121262.537-757\-\-\-\-\-\-\--\[[@bib70]\]COVID-19 team Australia02/1215438-6691 (6.7)\-\-\-\-\-\--\[[@bib71]\]Yueying et al.02/1363-15.2 - 44.933\-\-\-\-\-\-\--\[[@bib72]\]Li et al.02/13244312 - 848\-\-\-\-\-\-\--\[[@bib73]\]Feng et al.02/132140.925-636\-\-\-\-\-\-\--\[[@bib74]\]Liang et al.02/141590\--911130 (8.2)18 (1.1)2 (0.1)2 (0.1)-1 (0.06)\--\[[@bib41]\]Zhang et al.02/1593615-495-1 (11.1)1 (11.1)\-\-\-\--\[[@bib40]\]Feng et al.02/1715-4 - 145\-\-\-\-\-\-\--\[[@bib75]\]Wang et al.02/17348-14\-\-\-\-\-\-\--\[[@bib76]\]Xiaobo et al.02/215259.733.6-85.835-21 (40.4)9 (17.3)-5 (9.6)4 (7.7)2 (3.8)-\[[@bib52]\][^4]Table 3Clinical characteristics of the study subjects.Table 3AuthorDate (MM/DD)NN (%)ReferenceFeverCoughSore ThroatMyalgia or fatigueSputum productionHeadacheHaemoptisisDiarrhoeaDyspnoeaWMCHHHPNCI01/20136136 (100.0)136 (100.0)\-\-\-\-\--136 (100.0)\[[@bib64]\]Chaolin et al.01/244140 (97.6)31 (75.6)0 (0.0)18 (43.9)11 (26.8)3 (7.3)2 (4.9)1 (2.4)22 (53.7)\[[@bib5]\]Li et al.01/29425\-\-\-\-\-\-\-\--\[[@bib11]\]Chen et al.01/309982 (82.8)81 (81.8)5 (5.1)11 (11.1)-8 (8.1)-2 (2.0)31 (31.3)\[[@bib4]\]Chung et al.02/042114 (66.7)9 (42.9)-6 (28.6)-3 (14.3)\-\--\[[@bib65]\]Chen et al.02/062928 (96.6)21 (72.4)-12 (41.4)21 (72.4)2 (6.9)-4 (13.8)17 (58.6)\[[@bib66]\]Wang et al.02/07138136 (98.6)82 (59.4)24 (17.4)138 (100.0)37 (26.8)9 (6.5)-14 (10.1)43 (31.2)\[[@bib67]\]Kui et al.02/07137112 (81.8)66 (48.2)-44 (32.1)6 (4.4)13 (9.5)7 (5.1)11 (8.0)26 (19.0)\[[@bib68]\]Chang et al.02/071312 (92.3)6 (46.2)-3 (23.1)2 (15.4)3 (23.1)-1 (7.7)-\[[@bib69]\]To et al.02/1212\-\-\-\-\-\-\-\--\[[@bib70]\]COVID-19 team Australia02/121514 (93.3)11 (73.3)\-\-\-\-\-\--\[[@bib71]\]Yueying et al.02/1363\-\-\-\-\-\-\-\--\[[@bib72]\]Li et al.02/132419 (79.2)6 (25.0)-6 (25.0)-4 (16.7)\--2 (8.3)\[[@bib73]\]Feng et al.02/132118 (85.7)12 (57.1)4 (19.0)11 (52.4)6 (28.6)\-\-\--\[[@bib74]\]Liang et al.02/141590\-\-\-\-\-\-\-\--\[[@bib41]\]Zhang et al.02/1598 (88.9)5 (55.6)4 (44.4)4 (44.4)\-\-\-\--\[[@bib40]\]Feng et al.02/17155 (33.3)1 (6.7)\-\-\-\-\-\--\[[@bib75]\]Wang et al.02/173417 (50.0)13 (38.2)\-\-\-\-\-\--\[[@bib76]\]Xiaobo et al.02/215251 (98.1)40 (76.9)-6 (76.9)-3 (11.5)\--33 (63.5)\[[@bib52]\][^5]Table 4Laboratory characteristics of the study subjects.Table 4AuthorDate (MM/DD)NN (%)ReferenceLeucocytosisLeukopeniaLymphopeniaHigh ASTHigh CreatinineHigh Creatine kinaseHigh LDHHigh Troponin I, \>99th percAnemiaDecreased AlbuminHigh ALTHigh BilirubinErythrocyte sedimentation rate elevatedC-reactive protein, highSerum ferritinWMCHHHPNCI01/20136\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib64]\]Chaolin et al.01/244112 (29.3)10 (24.4)26 (63.4)15 (36.6)4 (9.8)13 (31.7)29 (70.7)5 (12.2)\-\-\-\-\-\--\[[@bib5]\]Li et al.01/29425\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib11]\]Chen et al.01/309924 (24.2)9 (9.1)35 (35.4)35 (35.4)3 (3.0)13 (13.1)75 (75.8)-50 (50.5)97 (98.0)28 (28.3)18 (18.2)84 (84.8)63 (63.6)62 (62.6)\[[@bib4]\]Chung et al.02/0421\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib65]\]Chen et al.02/06296 (20.7)6 (20.7)20 (69.0)7 (24.1)2 (6.9)-20 (69.0)\--15 (51.7)5 (17.2)1 (3.4)-27 (93.1)-\[[@bib66]\]Wang et al.02/071380 (0.0)0 (0.0)97 (70.3)\-\--55 (39.9)\-\-\-\-\-\-\--\[[@bib67]\]Kui et al.02/0713726 (19.0)51 (37.2)99 (72.3)\-\-\-\-\-\-\-\-\--115 (83.9)-\[[@bib68]\]Chang et al.02/0713\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib69]\]To et al.02/1212\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib70]\]COVID-19 team Australia02/1215\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib71]\]Yueying et al.02/1363\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib72]\]Li et al.02/1324-5 (20.8)2 (8.3)\-\-\-\-\-\-\-\--6 (25.0)12 (50.0)-\[[@bib73]\]Feng et al.02/1321\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib74]\]Liang et al.02/141590\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib41]\]Zhang et al.02/1591 (11.1)-2 (22.2)\-\-\-\-\-\-\-\-\--5 (55.6)-\[[@bib40]\]Feng et al.02/1715-8 (53.3)\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib75]\]Wang et al.02/17345 (14.7)1 (2.9)1 (2.9)\-\--10 (29.4)\-\-\-\--5 (14.7)1 (2.9)-\[[@bib76]\]Xiaobo et al.02/2152\-\-\-\-\-\-\-\-\-\-\-\-\-\--\[[@bib52]\][^6]Table 5Imaging and complications of the study subjects.Table 5AuthorDate (MM/DD)NN (%)ReferenceImagingComplicationsChest Ray Unilateral PneumoniaChest Ray Bilateral PneumoniaGround-glass opacityAcute respiratory distress syndromeRNAaemiaAcute cardiac injuryAcute kidney injurySecondary infectionShockHospitalizationDischargeDeathWMCHHHPNCI01/20136 - - - - - - - - - - -1 (0.7)\[[@bib64]\]Chaolin et al.01/2441-40 (97.6)40 (97.6)12 (29.3)6 (14.6)5 (12.2)3 (7.3)4 (9.8)3 (7.3)7 (17.1)28 (68.3)6 (14.6)\[[@bib5]\]Li et al.01/29425\-\-\--425 (100.0)\-\-\-\-\-\--\[[@bib11]\]Chen et al.01/309925 (25.3)74 (74.7)14 (14.1)17 (17.2)99 (100.0)-3 (3.0)-4 (4.0)57 (57.6)31 (31.3)11 (11.1)\[[@bib4]\]Chung et al.02/04212 (1.5)16 (11.8)18 (13.2)-21 (15.4)\-\-\--21 (15.4)\--\[[@bib65]\]Chen et al.02/0629\--29 (100.0)-29 (100.0)\-\-\--27 (93.1)-2 (6.9)\[[@bib66]\]Wang et al.02/071380 (0.0)138 (100.0)138 (100.0)27 (19.6)138 (100.0)10 (7.2)5 (3.6)-12 (8.7)138 (100.0)47 (34.1)6 (4.3)\[[@bib67]\]Kui et al.02/07137-36 (26.3)55 (40.1)-137 (100.0)\-\-\--77 (56.6)44 (32.4)16 (11.8)\[[@bib68]\]Chang et al.02/07131 (7.7)-6 (46.2)-13 (100.0)\-\-\--12 (92.3)1 (7.7)-\[[@bib69]\]To et al.02/1212\-\-\--12 (100.0)\-\-\--12 (100.0)\--\[[@bib70]\]COVID-19 team Australia02/1215\-\-\--15 (100.0)\-\-\--11 (73.3)\--\[[@bib71]\]Yueying et al.02/1363-38 (60.3)14 (22.2)-63 (100.0)\-\-\-\-\-\--\[[@bib72]\]Li et al.02/1324\-\-\--24 (100.0)\-\-\-\-\-\--\[[@bib73]\]Feng et al.02/132118 (85.7)\-\--21 (100.0)\-\-\--21 (100.0)\--\[[@bib74]\]Liang et al.02/141590\-\-\-\-\-\-\--1590 (100.0)\--\[[@bib41]\]Zhang et al.02/1592 (22.2)5 (55.6)7 (77.8)-9 (100.0)\-\-\--9 (100.0)\--\[[@bib40]\]Feng et al.02/17154 (26.7)8 (53.3)\--15 (100.0)\-\-\-\--15 (100.0)-\[[@bib75]\]Wang et al.02/1734-34 (100.0)34 (100.0)-34 (100.0)\-\-\--34 (100.0)34 (100.0)-\[[@bib76]\]Xiaobo et al.02/2152\-\--35 (67.3)-12 (23.1)15 (28.8)2 (3.8)-52 (100.0)-32 (61.5)\[[@bib52]\][^7]Table 6Meta-analysis outcomes (random-effects model).[a](#tbl6fna){ref-type="table-fn"}Table 6VariableNumber of StudiesMean (y-old) / Prevalence (%)95%CInQ[b](#tbl6fnb){ref-type="table-fn"}I^2^[c](#tbl6fnc){ref-type="table-fn"}t^2^[d](#tbl6fnd){ref-type="table-fn"}PAge1851.9746.06-57.8926261193.2898.56145.687**\<0.001**Male2255.951.6-60.1287461.9866.120.005**\<0.001**ICU620.310.0-30.6188349.4989.890.013**\<0.001***Comorbidities*736.824.7-48.950547.7587.440.022**\<0.001** Hypertension518.68.1-29.036323.98983.330.011**\<0.001** Cardiovascular disease614.45.7-23.148545.2988.960.01**\<0.001** Diabetes811.99.1-14.65234.0650.000.000.772 Chronic obstructive pulmonary disease61.80.6-3.04854.4130.000.000.492 Malignancies62.50.7-4.24967.5934.160.000.180 Chronic liver disease33.00.7-5.42080.7440.000.000.689*Clinical manifestations*Fever1588.784.5-92.9784128.7389.120.04**\<0.001** Adult1392.889.4-96.273568.2582.420.002**\<0.001** Children243.928.2-59.6491.2520.20.0030.263Cough1557.640.8-74.4784657.7697.870.102**\<0.001** Adult1363.448.0-78.8735413.0597.090.072**\<0.001** Children222.00.0-52.9498.98388.870.044**0.003**Dyspnea845.610.9-80.46561346.8699.480.248**\<0.001**Myalgia or fatigue1129.419.8-39.044646.5380.660.017**\<0.001**Sputum production628.510.8-46.337994.9494.730.044**\<0.001**Sore throat511.02.8-19.230828.2485.390.006**\<0.001**Headache98.05.7-10.25545.0480.000.000.752Diarrhea66.12.4-9.745713.1962.110.001**0.022***Laboratory findings*Decreased Albumin275.830.5-100.012824.2995.880.103**\<0.001**High C-reactive protein658.321.8-94.7332472.3498.940.200**\<0.001**High LDH557.038.0-76.034154.0392.590.043**\<0.001**Lymphopenia843.118.9-67.3511349.1897.990.117**\<0.001**High Erythrocyte sedimentation rate341.80.0-92.8157118.5598.310.199**\<0.001**High AST333.326.3-40.41691.70.000.000.427High ALT224.113.5-34.61281.74942.840.0030.186High Creatinine Kinase221.33.2-39.41405.3681.360.014**0.021**Leukopenia818.78.5-28.8517126.8094.480.018**\<0.001**Leukocytosis716.85.5-28.048787.4793.140.019**\<0.001**High Bilirubin210.70.0-25.11288.1987.790.01**0.004**High Creatinine34.51.0-8.01692.2310.170.000.328*Chest X-Ray Pneumonia Compromise* Unilateral725.05.2-44.8316165.3196.370.065**\<0.001** Bilateral972.958.6-87.1557463.6498.280.042**\<0.001** Adult770.750.4-91.0508451.5998.670.070**\<0.001** Children277.733.5-100.04912.0491.690.094**\<0.001** Image findings Ground-glass opacity1068.551.8-85.2584992.399.090.068**\<0.001***Complications*RNAemia1896.894.9-98.71096241.1992.950.001**\<0.001** Adult1696.694.6-98.61047240.5993.770.001**\<0.001** Children298.394.7-100.0490.1250.000.000.723Acute respiratory distress syndrome432.813.7-51.833049.4993.930.035**\<0.001**Acute cardiac injury313.04.1-21.92316.7270.220.004**0.035**Acute kidney injury47.91.8-14.033016.581.850.003**\<0.001**Shock36.23.1-9.32782.3414.670.000.310Secondary infections25.60.3-10.9931.2218.160.000.269Hospitalization1587.984.2-91.62211390.7696.420.004**\<0.001***Outcome*Discharged752.923.9-81.8477548.7798.910.15**\<0.001**Death713.96.2-21.5632107.1791.40.009**\<0.001**[^8][^9][^10][^11]

4.2. Demographical characteristics and comorbidities {#sec4.2}
----------------------------------------------------

The mean age of patients across 18 studies was 51.97 years old (95%CI 46.06--57.89), being male 55.9% (95%CI 51.6--60.1%). Patients presented in 36.8% of cases with comorbidities (95%CI 24.7--48.9%), the most significant being hypertension (18.6%, 95%CI 8.1--29.0%), cardiovascular disease (14.4%, 95%CI 5.7--23.1%), and diabetes (11.9%, 95%CI 9.1--14.6%), among others ([Table 6](#tbl6){ref-type="table"}) ([Fig. S2](#appsec1){ref-type="sec"}).

4.3. Clinical manifestations and laboratory findings {#sec4.3}
----------------------------------------------------

Regarding the clinical manifestations, fever (88.7%, 95%CI 84.5--92.9%), cough (57.6%, 95%CI 40.8--74.4%) and dyspnea (45.6%, 95%CI 10.9--80.4%) were the most prevalent clinical manifestations ([Table 6](#tbl6){ref-type="table"}). Fever frequency was significantly higher in adults compared to children (92.8%, 95%CI 89.4--96.2%; versus 43.9%, 95%CI 28.2--59.6%) ([Fig. S2](#appsec1){ref-type="sec"}).

Regarding laboratory findings, decreased albumin (75.8%, 95%CI 30.5--100.0%), high C-reactive protein (58.3%, 95%CI 21.8--94.7%), and high lactate dehydrogenase (LDH) (57.0%, 95%CI 38.0--76.0), lymphopenia (43.1%, 95%CI 18.9--67.3), and high erythrocyte sedimentation rate (ESR) (41.8%, 95%CI 0.0--92.8), were the most prevalent laboratory results ([Table 6](#tbl6){ref-type="table"}) ([Fig. S2](#appsec1){ref-type="sec"}).

4.4. Imaging, complications, and outcomes {#sec4.4}
-----------------------------------------

At the chest X-rays, the pneumonia compromise was predominantly bilateral (72.9%, 95%CI58.6--87.1), with image findings ground-glass opacity in 68.5% (95%CI 51.8--85.2) ([Table 6](#tbl6){ref-type="table"}) ([Fig. S2](#appsec1){ref-type="sec"}) in those with X-ray results.

Among the patients, 20.3% (95%CI 10.0--30.6%) who required ICU, 32.8% presenting with ARDS (95%CI 13.7--51.8), 13.0% with acute cardiac injury (95%CI 4.1--21.9%), 7.9% with acute kidney injury (95%CI 1.8--14.0%), 6.2% (95%CI 3.1--9.3%) with shock and 13.9% (95%CI 6.2--21.5%) had fatal outcomes ([Table 6](#tbl6){ref-type="table"}). RNAemia (detection of viral RNA in blood) was reported 96.8% of the all patients (95%CI 94.9--98.7%) ([Table 6](#tbl6){ref-type="table"}) ([Fig. S2](#appsec1){ref-type="sec"}), and also in nasopharyngeal aspirates (NPA).

4.5. Case reports {#sec4.5}
-----------------

We found 39 case report articles ([Table S1](#appsec1){ref-type="sec"}, summarizing 126 cases of COVID-19. The mean age was 47.9 y-old (SD 22.2), being male 69.01% of those with sex identified in the article ([Table 7](#tbl7){ref-type="table"} ). From the total, 10.3% presented hypertension as comorbidity, followed by other conditions. The more common clinical features were fever (77.0%), cough (55.6%), and myalgia (31.0%), among others ([Table 7](#tbl7){ref-type="table"}). Regarding the laboratory findings, lymphopenia was the more frequent (23.8%), followed by high C-reactive protein (22.2%) and high aspartate transaminase (AST) (7.9%). At the chest X-ray, 46% presented ground-glass opacity, with a bilateral compromise in 39.7% of the patients. All the case reports had RNAaemia. For the complications, 7.1% presented with ARDS, and 1.6% with secondary infections, among others. Most of the cases described in these case reports were hospitalized (74.6%), with a fatality rate of 15.9% ([Table 7](#tbl7){ref-type="table"}).Table 7Summary of the case report findings.[a](#tbl7fna){ref-type="table-fn"}Table 7VariablesN (126)%VariablesN (126)%Age (y-old) (mean, SD) (n = 118)47.922.2*Images*Sex (Male/Female) (n = 71)4969.01Ground-glass opacity at chest X-ray5846.0ICU (Yes)118.7Chest X-Ray Bilateral Pneumonia5039.7*Comorbidities*Chest X-Ray Unilateral Pneumonia1310.3Hypertension1310.3*Complications*Chronic liver disease54.0RNAaemia126100.0Cardiovascular disease32.4Acute respiratory distress syndrome97.1Chronic obstructive pulmonary disease21.6Secondary infection21.6Malignancy or cancer10.8Acute kidney injury10.8*Clinical features*Shock10.8Fever9777.0Hospitalization9474.6Cough7055.6*Outcomes*Myalgia or fatigue3931.0Discharge4838.1Dyspnoea2721.4Death2015.9Sputum production1612.7Sore Throat1310.3*Countries of the case report articles (39)*Diarrhoea86.3China2564.1Headache75.6South Korea410.3Haemoptisis10.8Australia12.6*Laboratory findings*Canada12.6Lymphopenia3023.8France12.6High C-reactive protein2822.2Germany12.6High AST107.9Japan12.6Leukopenia97.1Nepal12.6High ALT97.1Taiwan12.6High LDH86.3Thailand12.6High Erythrocyte sedimentation rate64.8United States of America12.6Leukocytosis43.2Vietnam12.6Anemia43.2*Countries of the cases reported (n = 126)*Decreased Albumin32.4China10180.2High Creatinine21.6South Korea64.8High Creatine kinase21.6Germany54.0High Bilirubin10.8France32.4Australia21.6Taiwan21.6Vietnam21.6Canada10.8Japan10.8Nepal10.8Thailand10.8United States of America10.8[^12]

5. Discussion {#sec5}
=============

Over the last two months, more than 156,000 cases of a new infectious disease have been confirmed in China and other countries in Asia, Pacific, Europe, Africa, and the Americas \[[@bib22],[@bib23],[@bib42], [@bib43], [@bib44]\]. The COVID-19 is an emerging condition that primarily threatens the preparedness and biosecurity conditions of all countries on this planet \[[@bib45]\]. Preparedness at different levels, facing a new clinical disease, demands efforts in epidemiological, diagnostic, therapeutic, and preventive fields during a potential pandemic \[[@bib46]\], that threatens to spread to new territories (\>115) and areas with the risk of epidemics.

Clinical, laboratory, image findings, as well as the factors associated with evolution of the disease and outcomes, constitute critical knowledge that should be carefully studied when a new infectious disease emerges. Recently, in this context of the COVID-19 outbreak, several questions have been raised, including what is the full spectrum of disease severity (which can range from asymptomatic, to symptomatic-but-mild, to severe, to requiring hospitalization, to fatal)? \[[@bib47]\]. In this systematic review and random-effects meta-analysis, we tried to initially summarize clinical data on COVID-19 confirmed cases that were published during the first weeks of the outbreak. We managed to analyze more than 780 patients for major clinical manifestations and up to half of them for their associated significant laboratory findings. Our findings are robust due to the pooled results after combining all the studies, which can be seen in forest plots for each of the variables. We used a random-effects meta-analysis model. This involves an assumption that the effects being estimated in the different studies are not identical, but follow some distribution. For random-effects analyses, the pooled estimate and 95%CIs refer to the center of the distribution of pooled prevalence but do not describe the width of the distribution. Often the pooled estimate and its 95%CI are quoted in isolation as an alternative estimate of the quantity evaluated in a fixed-effect meta-analysis, which is inappropriate. The 95%CI from a random-effects meta-analysis describes uncertainty in the location of the mean of systematically different prevalence in the different studies \[[@bib38],[@bib39]\].

As expected from initial observations in China \[[@bib4],[@bib5],[@bib11]\], COVID-19 patients presented predominantly with fever and cough, which appears to be more frequent in adults than children, as well as dyspnea, and myalgia, among other clinical features. This was consistently found not only in the studies meta-analyzed here but also in the case reports included in this systematic review. Fever frequency is similar in SARS and MERS, but the cough frequency is higher in SARS and COVID-19 than MERS (\<50%) \[[@bib28],[@bib48],[@bib49]\]. In SARS and MERS, diarrhea is reported in 20--25% of patients \[[@bib50]\], here we found it in less than 7%, at the studies ([Table 6](#tbl6){ref-type="table"}) and case reports ([Table 7](#tbl7){ref-type="table"}). Of note, in the case reports, myalgia was the third most common reported symptom after fever and cough. Most patients required hospitalization, often attributed to the patient\'s comorbidities, as observed in a third of the cases. We found that approximately 20% of those hospitalized needed to be admitted to ICU for critical management. Unlike SARS, with it is well-characterized two-stage clinical course of the disease, COVID-19, still needs further definition \[[@bib48]\]. The first week of the condition is also similar, coinciding with recent data of the viral load during this stage \[[@bib51]\]. However, case-control studies and cohort studies are necessary to define the clinical evolution of disease better. A second stage, as occurs in SARS, might also be seen in COVID-19, with the lower respiratory tract bilateral compromise, observed in more than 72% of the patients across nine studies with more than 500 patients, also experiencing a dry cough, and dyspnea \[[@bib5],[@bib48],[@bib52]\] and with chest X-ray images of ground-glass opacity frequently observed in two-thirds of patients -- this is also seen in SARS \[[@bib53]\].

The laboratory abnormalities predominantly found included hypoalbuminemia, elevated inflammatory markers, such as C-reactive protein, LDH, and ESR, among others. Also, lymphopenia is consistently present in more than 40% of the patients across eight studies with more than 500 patients. Data from the 2002--2003 outbreak indicate that SARS may be associated with lymphopenia, leukopenia, and thrombocytopenia, elevated levels of LDH, alanine transaminase (ALT), AST, and creatine kinase \[[@bib54],[@bib55]\], but also, and not significantly seen, nor consistently reported, in COVID-19 studies and cases, with thrombocytopenia, mild hyponatremia, and hypokalemia. The frequency of lymphopenia found suggests that COVID-19 might act on lymphocytes, especially T lymphocytes, as does SARS-CoV, maybe including depletion of CD4 and CD8 cells \[[@bib4]\]. Virus particles spread through the respiratory mucosa, initially using the ACE2 receptor at ciliated bronchial epithelial cells, and then infect other cells. This induces a cytokine storm in the body and generates a series of immune responses, that cause changes in peripheral white blood cells and immune cells such as lymphocytes \[[@bib56],[@bib57]\].

With regard to complications and death, a third of patients presented with ARDS, but also, albeit in a lower frequency, acute cardiac injury, acute kidney injury, and shock, eventually followed by multiple organ failure. Therefore, early identification and timely treatment of critical cases are of crucial importance \[[@bib4]\]. We observed a CFR of over 13% in 7 studies describing 632 hospitalized patients. In two studies in China (n = 41, n = 99), the case fatality rates were 15% \[[@bib5]\] and 11% \[[@bib4]\], respectively. Crude surveillance data \[[@bib42]\], indicated that till March 14, 2020, from 156,106 reported cases, 5,829 patients have died (3.73%), with \>52% of the deaths occurring in China (3,085), followed by Italy with 24.72% (1,441). This differs from the CFR found in our systematic review and may be explained by the fact that cases requiring medical attention in hospitals were the patients included in the studies selected for analysis, and that consequently they consulted with an advanced stage of disease leading to hospitalization. Even, from the crude epidemiological data reported by the countries, some of them have reported a higher proportion of deaths, as is the case of Australia (3.75%), China (3.86%), Iran (4.8%), Italy (6.81%, 1,441 deaths/21,157 cases), Argentina (8.33%), and Iraq (10.0%). Thus, the CFR in different settings needs further reassessment. More studies are needed to elucidate the risk factors for severe illness and death. This will allow for the identification of groups most likely to have poor outcomes so that we can focus on prevention and treatment efforts? \[[@bib47]\].

After the development of this systematic review (SR), and even availability on a preprint server, online Feb. 25, 2020 (<https://www.preprints.org/manuscript/202002.0378/v3>); a brief systematic review and meta-analysis, only addressing few variables, such as fever, cough, muscle soreness or fatigue, ARDS, abnormal chest CT, patients in critical condition and death of patients with COVID-19, was published (Feb. 28, 2020) \[[@bib58]\]. This review was based on ten studies, using a random effect model, as we did. On March 12, 2020 (two days before the proofs correction of this article), another systematic review was electronically published ahead at International Journal of Infectious Diseases (<https://doi.org/10.1016/j.ijid.2020.03.017>), assessing the prevalence of comorbidities in the COVID-19 infection patients and the risk of underlying diseases in severe patients compared to non-severe patients. They found similar results: fever (91%, 95%CI 86--97%), followed by cough (67%, 95%CI 59--76%), fatigue (51%, 95%CI 34--68%), and dyspnea (30%, 95%CI 21--40%). The most prevalent comorbidity were hypertension (17%, 95%CI 14--22%), and diabetes (8%, 95%CI 6--11% ), followed by cardiovascular diseases (5%, 95%CI 4--7%), and respiratory system disease (2%, 95%CI 1--3%). They did not assessed other clinical manifestations, nor any laboratory or imaging findings, nor complications.

Comparing their findings \[[@bib58]\] with ours, they found fever in 89.8% (95%CI 81.8--94.5%) of patients, this SR found 88.7% (95%CI 84.5--92.9%), but we assessed differences, as mentioned above, between adults and children, and they did not. For cough, based on the 95%CI, there were not significant differences too, between that SR and the current, 72.2% (95%CI 65.7--78.2%) versus 57.6% (95%CI 40.8--74.4%). For fatigue, there is a variation in frequency between both studies, 42.5% (95%CI 21.3--65.2%) versus 29.4% (95%CI 19.8--39.0%). Sun et al. did not assess other clinical manifestations \[[@bib58]\], we were able to do it for eight of the studies included in this systematic review. Both reviews are clear and consistent in that more than 80% of the patients presented with fever, more than half with cough, and more than a third with fatigue. That SR did not assess any laboratory findings, but evaluated the frequency of patients presenting ADRS which was found to be 14.8% (95%CI 4.6--29.6%), which was also consistent with our study, 32.8% (95%CI 13.7--51.8%), which although higher, was not significantly so. For patients admitted to ICU, there were also small differences. Sun et al. found 18.1% (95%CI 12.7--24.3%), however, we identified that 20.3% required intensive critical care (95%CI 10.0--30.6%). The major difference between both studies was in the last variable assessed i.e. the case fatality rate. Sun et al. report 4.3% (95%CI 2.7--6.1%) and we report a rate of 13.9% (95%CI 6.2--21.5%), which is significantly higher. Finally, Sun et al. only included studies, but not case reports, as we did, which provided additional consistent findings of the clinical, laboratory, imaging and evolution characteristics of patients with confirmed COVID-19.

Our results showed that there is still a need for more comprehensive clinical studies, including short and long -term follow-up cohort assessments. More studies from outside China, where there are more than 100 patients diagnosed with COVID-19, as is the case of South Korea, Italy, and Japan \[[@bib59],[@bib60]\], will contribute to the growing volume of data, in addition to the growing number of studies appearing from China. Even more, the situation with the cruise ship Diamond Princess, docked in Yokohama, Japan, with 3711 passengers, approximately 20% of the infected, with 7 deaths, is also a valuable chance to better characterize COVID-19. Clinical evidence synthesized in this review is mainly derived from China, although for case reports, ten of the thirty-two countries with confirmed cases \[[@bib7],[@bib12],[@bib29],[@bib30]\], have published some of them ([Table 7](#tbl7){ref-type="table"}). Further clinical data is crucial to elucidate the clinical spectrum of the disease. The clinical experience stemming from countries now dealing with an ever increasing number of cases such as Italy \[[@bib61]\], Singapore, Hong Kong, Nepal \[[@bib7]\], Iran, and Malaysia in the form of case reports, case series, or large observational studies will be most important. Up to now, regardless whether of report type (cross-sectional studies or case reports) the clinical findings are consistent, but more data are needed to define the risk factors for admission in ICU and for fatal outcomes. However, data suggest that older age and comorbidities play a vital role in influencing severe disease and negative clinical outcomes. These data would be useful to guide patient risk groups management in the current epidemic, especially in those countries about to receive cases, as is the situation in Latin America. COVID-19 cases have been confirmed in Brazil, Mexico, and in all the countries of South America, and in most of the Central America and the Caribbean subregions, as of the time of proofs correction (March 14, 2020) \[[@bib62]\]. In these and other resource-constrained settings, e.g. Africa, supplies chains, including those for drugs, masks and personal protection equipment, will be challenged.

The results of this systematic review highlight the clinical, laboratory, and imaging findings that may assist clinicians anywhere in the globe in suspecting the possibility of COVID-19 infection in those with recent travel to areas with ongoing transmission or among contacts of confirmed cases. Early recognition of cases will allow clinicians to ensure adequate clinical monitoring, institution of supportive interventions, and preventing further transmission by implementing infection control measures \[[@bib29],[@bib56],[@bib63]\]. There is a need for prospective studies to evaluate the epidemiology, pathogenesis, duration of viral shedding, and the clinical spectrum of disease associated with this emerging viral infection \[[@bib29],[@bib56],[@bib63]\].

To effectively protect populations and healthcare workers in the face of arrival and spreading of this emerging viral pathogen, constant evaluation of available evidence is essential to guide clinical suspicion, diagnosis, management, and mitigation of transmission of COVID-19.

5.1. Limitations {#sec5.1}
----------------

This review has several limitations. Few studies are available for inclusion. Most are from China. Now urgently, data from Italy are required. It would be better to include as many studies with a broad geographic scope, to get a more comprehensive understanding of COVID19. More detailed patient information, particularly regarding clinical outcomes, was unavailable in most studies at the time of analyses; however, the data in this review permit a first synthesis of the clinical and laboratory characteristics of COVID-19. Our systematic review and meta analysis found a CFR of over 13%. As we discussed earlier, the differences between the crude fatality rate (\<3.5%) and that found among hospitalized patients in the selected studies included here may be explained by the fact that cases requiring medical attention in hospitals consulted with a more advanced stage of disease,.

6. Conclusions {#sec6}
==============

Infection with COVID-19 is associated with significant morbidity especially in patients with chronical medical conditions. At least one-fifth of cases require supportive care in medical intensive care units, which is especially limited in most developing countries. Despite the implementation of optimal supportive interventions, case fatality rate among hospitalized patients is more than 10%. Similar to other viral respiratory pathogens, COVID-19 presents in the majority of cases with a rapidly progressive course of fever, cough and dyspnea. Important distinguishing factors are leukopenia and the rapid progression to ARDS. Eliciting a history of recent travel to areas with ongoing outbreaks of this emerging pathogen or contact with a confirmed case of COVID-19, should prompt clinicians to initiate isolation precautions and obtain laboratory confirmation. Additional research is needed to elucidate viral and host factors in the pathogenesis of severe and fatal infections.
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[^1]: Both authors contributed equally. Order was decided by seniority.

[^2]: WMCHHHPNCI, Wuhan Municipal Commission of Health and Health on Pneumonia of New Coronavirus Infection. MM/DD, Month, Day.

[^3]: Quality score ranged, 0--20. Based on the Appraisal Tool for Cross-Sectional Studies, AXIS \[[@bib36]\].

[^4]: WMCHHHPNCI, Wuhan Municipal Commission of Health and Health on Pneumonia of New Coronavirus Infection. MM/DD, Month, Day. ICU, intensive care unit requirement. y-old, years old. -, Not available, not reported.

[^5]: WMCHHHPNCI, Wuhan Municipal Commission of Health and Health on Pneumonia of New Coronavirus Infection. MM/DD, Month, Day. -, Not available, not reported.

[^6]: WMCHHHPNCI, Wuhan Municipal Commission of Health and Health on Pneumonia of New Coronavirus Infection. MM/DD, Month, Day. LDH, Lactate dehydrogenase. AST, Aspartate transaminase. ALT, Alanine transaminase. -, Not available, not reported.

[^7]: WMCHHHPNCI, Wuhan Municipal Commission of Health and Health on Pneumonia of New Coronavirus Infection. MM/DD, Month, Day. ICU, intensive care unit. y-old, years old. AST, Aspartate transaminase. ALT, Alanine transaminase. -, Not available, not reported.

[^8]: 95% CI = 95% confidence interval; ICU, intensive care unit. y-old, years old. AST, Aspartate transaminase. ALT, Alanine transaminase.

[^9]: Cochran\'s Q statistic for heterogeneity.

[^10]: I^2^ Index for the degree of heterogeneity.

[^11]: Tau-squared measure of heterogeneity.

[^12]: The list of case reports is available at [Table S1](#appsec1){ref-type="sec"}---supplemental materials.
